

Outlook Therapeutics, Inc. Logo

Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

ISELIN, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that [C. Russell Trenary, President and Chief Executive Officer](#) of Outlook Therapeutics, will participate in a fireside chat during the virtual [H.C. Wainwright 23rd Annual Global Investment Conference](#) being held September 13 – 15, 2021.

In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the [conference website](#).

A [video webcast](#) of the fireside chat will be available for viewing on-demand beginning Monday, September 13, 2021 at 7:00 AM ET for those registered for the event and accessible on the [Events](#) page in the [Investors](#) section of the Outlook Therapeutics website (outlooktherapeutics.com) for 90 days.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHS 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:

Media Inquiries:

Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com



Source: Outlook Therapeutics, Inc.